Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). The new drug Areplivir® Zinc as a combination of favipiravir (200 mg) and zinc...

Full description

Saved in:
Bibliographic Details
Main Authors: T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2024-03-01
Series:Разработка и регистрация лекарственных средств
Subjects:
favipiravir
zinc
covid-19
pharmacokinetics
Online Access:https://www.pharmjournal.ru/jour/article/view/1769
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.pharmjournal.ru/jour/article/view/1769

Similar Items